Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?

被引:8
作者
De Marco, Davide
Pencina, Karol
Pencina, Michael
Dufresne, Line
Thanassoulis, George
Sniderman, Allan D. [1 ]
机构
[1] McGill Univ, Royal Victoria Hosp, Mike & Valeria Rosenbloom Ctr Cardiovasc Prevent, Dept Med,Hlth Ctr, Glen Site,C04 4180,1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada
关键词
Triglycerides; Apo B; Guidelines; LDL-C/Apo B ratio; Small dense LDL; ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-B; DENSE LDL; PLASMA; TRIGLYCERIDE; DISEASE; RISK;
D O I
10.1016/j.jacl.2023.05.093
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Because cholesterol-depleted Apo B particles are thought to be a hallmark of hypertriglyceridemia, American, Canadian and European Lipid Guidelines suggest screening for Apo B only in patients with hypertriglyceridemia. Accordingly, this study examines the relationship of triglycerides to the LDL-C/Apo B and non-HDL-C/Apo B ratios.Methods: The study cohort consisted of 6272 NHANES subjects adjusted for a weighted sample size of 150 million subjects without previously diagnosed cardiac disease. Data was reported by LDL-C/Apo B tertiles as weighted frequencies and percent. Sensitivity, specificity, negative predictive and positive predictive values were calculated for triglycerides thresholds of > 150 mg/dL and > 200 mg/dL. The range of values of Apo B for decisional levels of LDL-C and non-HDL-C were also determined Results: Among patients with triglycerides > 200 mg/dL, 75.9% were amongst the lowest LDL-C/Apo B tertile. However, this represents only 7.5% of the total population. Of patients with the lowest LDL-C/Apo B ratio, 59.8% had triglycerides < 150 mg/dL. Moreover, there was an inverse relationship between non-HDL-C/Apo B such that elevated triglycerides were associated with the highest tertile of non-HDL-C/Apo B. Finally, the range of values of Apo B for decisional levels of LDL-C and non-HDL-C was determined and is so broad-30.3-40.6 mg/dl Apo B for different levels of LDL-C and 19.5 to 27.6 mg/dl Apo B for different levels of non-HDL-C-that neither is an adequate clinical surrogate for Apo B.Conclusion: Plasma triglycerides should not be used to restrict the measurement of Apo B since cholesterol-depleted Apo B particles may be present at any level of triglyceride.(c) 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:452 / 457
页数:6
相关论文
共 33 条
[1]   Metabolic origins and clinical significance of LDL heterogeneity [J].
Berneis, KK ;
Krauss, RM .
JOURNAL OF LIPID RESEARCH, 2002, 43 (09) :1363-1379
[2]   Enhanced cholesterol efflux promotion in well-trained soccer players [J].
Brites, F ;
Verona, J ;
De Geitere, C ;
Fruchart, JC ;
Castro, G ;
Wikinski, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (10) :1262-1267
[3]   MOLECULAR-BASIS OF LIPID TRANSFER PROTEIN-DEFICIENCY IN A FAMILY WITH INCREASED HIGH-DENSITY LIPOPROTEINS [J].
BROWN, ML ;
INAZU, A ;
HESLER, CB ;
AGELLON, LB ;
MANN, C ;
WHITLOCK, ME ;
MARCEL, YL ;
MILNE, RW ;
KOIZUMI, J ;
MABUCHI, H ;
TAKEDA, R ;
TALL, AR .
NATURE, 1989, 342 (6248) :448-451
[4]  
Chen Te-Ching, 2018, Vital Health Stat 2, P1
[5]   Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial [J].
Chiu, Sally ;
Williams, Paul T. ;
Krauss, Ronald M. .
PLOS ONE, 2017, 12 (02)
[6]   Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease [J].
Ference, Brian A. ;
Kastelein, John J. P. ;
Ray, Kausik K. ;
Ginsberg, Henry N. ;
Chapman, John ;
Packard, Chris J. ;
Laufs, Ulrich ;
Oliver-Williams, Clare ;
Wood, Angela M. ;
Butterworth, Adam S. ;
Di Angelantonio, Emanuele ;
Danesh, John ;
Nicholls, Stephen J. ;
Bhatt, Deepak L. ;
Sabatine, Marc S. ;
Catapano, Alberico L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (04) :364-373
[7]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[8]   ROLE OF PLASMA TRIGLYCERIDE IN THE REGULATION OF PLASMA LOW-DENSITY-LIPOPROTEIN (LDL) SUBFRACTIONS - RELATIVE CONTRIBUTION OF SMALL, DENSE LDL TO CORONARY HEART-DISEASE RISK [J].
GRIFFIN, BA ;
FREEMAN, DJ ;
TAIT, GW ;
THOMSON, J ;
CASLAKE, MJ ;
PACKARD, CJ ;
SHEPHERD, J .
ATHEROSCLEROSIS, 1994, 106 (02) :241-253
[9]  
Grundy SM, 2019, CIRCULATION, V139, pE1082, DOI 10.1161/CIR.0000000000000625
[10]   Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab [J].
Hagstrom, Emil ;
Steg, P. Gabriel ;
Szarek, Michael ;
Bhatt, Deepak L. ;
Bittner, Vera A. ;
Danchin, Nicolas ;
Diaz, Rafael ;
Goodman, Shaun G. ;
Harrington, Robert A. ;
Jukema, J. Wouter ;
Liberopoulos, Evangelos ;
Marx, Nikolaus ;
McGinniss, Jennifer ;
Manvelian, Garen ;
Pordy, Robert ;
Scemama, Michel ;
White, Harvey D. ;
Zeiher, Andreas M. ;
Schwartz, Gregory G. .
CIRCULATION, 2022, 146 (09) :657-672